Literature DB >> 28818111

Estimates of cancer incidence and mortality in China, 2013.

Rongshou Zheng1, Hongmei Zeng1, Siwei Zhang1, Wanqing Chen2.   

Abstract

INTRODUCTION: Population-based cancer registration data are collected by the National Central Cancer Registry in China every year. Cancer incident cases and cancer deaths in 2013 were analyzed.
METHODS: Through the procedure of quality control, reported data from 255 registries were accepted to establish the national database for cancer estimates. Incidences and mortalities were calculated with stratification by area (urban/rural), sex (male/female), age group (0, 1-4, 5-9, 10-14 … 80-84, and 85-year-old and above), and cancer site. The structure of Segi's population was used for the calculation of age-standardized rates (ASR). Top 10 most common cancers and leading causes of cancer deaths were listed.
RESULTS: In 2013, 3,682,200 new cancer cases and 2,229,300 cancer deaths were estimated in China based on the pooled data from 255 cancer registries, covering 16.65% of the national population. The incidence was 270.59/100,000, with an ASR of 186.15/100,000; the mortality was 166.83/100,000, with an ASR of 108.94/100,000. The top 10 most common cancer sites were the lung, stomach, liver, colorectum, female breast, esophagus, thyroid, cervix, brain, and pancreas. The ten leading causes of cancer deaths were lung cancer, liver cancer, gastric cancer, esophageal cancer, colorectal cancer, pancreatic cancer, female breast cancer, brain tumor, leukemia, and lymphoma.
CONCLUSIONS: Cancer leaves serious disease burden in China with high incidence and mortality. Lung cancer was the most common cancer and the leading cause of cancer death in China. Efficient control strategy is needed, especially for major cancers.

Entities:  

Keywords:  Cancer registry; China; Epidemiology; Incidence; Mortality

Mesh:

Year:  2017        PMID: 28818111      PMCID: PMC5561600          DOI: 10.1186/s40880-017-0234-3

Source DB:  PubMed          Journal:  Chin J Cancer        ISSN: 1944-446X


The National Central Cancer Registry (NCCR) collects data from local registries in China every year and publishes annual cancer statistics of China. In 2016, the collection of cancer registration data in 2013 was completed, and data analysis was done for publication. We reported the main results of cancer incidence and mortality in China Cancer [1] and Cancer Letters [2]. In the present paper, the cancer statistics were briefly introduced based on the published papers. A total of 347 cancer registries submitted registration data of 2013 to NCCR in 2016. The number of registries increased compared with 261 cancer registries in 2012 [3]. Submitted data were checked following the quality control procedure. After several rounds of feedback and re-submission, the data from 255 registries were qualified for final database input and accepted for analysis. In local registries, data resources include hospitals, clinics, community health centers, medical insurance departments, and death registries. Demographic data were obtained from local statistical bureaus or household register departments in local public security bureaus. Proportion of morphological verification (MV %), percentage of cancer cases identified with death certification only (DCO %), mortality to incidence (M/I) ratio, percentage of uncertified cancer, and percentage of cancer with undefined or unknown primary site were the key indicators for evaluating data completeness, validity, and reliability. Changes of incidences and mortalities by year were also calculated. Pooled data were stratified by area (urban/rural), sex (male/female), age group (0, 1–4, 5–9, 10–14 … 80–84 85-year-old and above), and cancer site. The Chinese standard population in 2000 and the world Segi’s population were used for the calculation of age-standardized incidence/mortality rates. The nation-wide cancer incident cases and cancer deaths were estimated using age-specific rates stratified by area, sex, caner site, and corresponding national population in 2013. The valid 255 cancer registries were composed of 88 urban and 167 rural registries, covering 226,494,490 citizens, accounting for 16.65% of the national population in 2013. The MV %, DCO %, and M/I ratio of overall cancers were 68.04, 1.74%, and 0.62, respectively. We estimated that about 3,682,000 new cancer cases were diagnosed in 2013 (Table 1). The incidence of all cancers was 270.59/100,000 (293.79/100,000 in males and 246.21/100,000 in females). The age-standardized incidence rates adjusted by the Chinese standard population (ASIRC) and by the world Segi’s population (ASIRW) were 190.17/100,000 and 186.15/100,000. The cumulative incidence rate from birth to 74-year-old was 21.60%. The cancer incidence in urban areas was higher than that in rural areas (crude incidence 283.79/100,000 vs. 255.27/100,000; ASIRC 193.53/100,000 vs. 185.42/100,000; ASIRW 188.87/100,000 vs. 182.35/100,000).
Table 1

Estimated cancer incidence in China in 2013.

This Table was published previously and is reproduced with permission from China Cancer [1]

AreasSexCases (×1000)Crude incidence (1/105)ASIRC (1/105)ASIRW (1/105)Cumulative rate 0–74 years (%)
AllBoth3682.0270.59190.17186.1521.60
Male2048.6293.79212.30210.7425.00
Female1633.4246.21170.38163.9318.28
UrbanBoth2074.9283.79193.53188.8721.68
Male1117.6299.49209.81207.9124.48
Female957.3267.43179.95172.5419.06
RuralBoth1607.1255.27185.42182.3521.45
Male931.0287.24215.07213.9525.62
Female676.1221.34157.71152.7317.25

ASIRC age-standardized incidence rate adjusted by the China standard population in 2000, ASIRW age-standardized incidence rate adjusted by the world Segi’s population

Estimated cancer incidence in China in 2013. This Table was published previously and is reproduced with permission from China Cancer [1] ASIRC age-standardized incidence rate adjusted by the China standard population in 2000, ASIRW age-standardized incidence rate adjusted by the world Segi’s population About 2,229,300 cancer deaths were estimated in 2013 all over the country (Table 2). The crude mortality was 163.83/100,000 (201.67/100,000 in males and 124.06/100,000 in females), and age-standardized mortality rates adjusted by the Chinese standard population (ASMRC) and by the world Segi’s population (ASMRW) were 109.95/100,000 and 108.94/100,000. The cumulative mortality rate from 0 to 74-year-old was 12.33%. The cancer mortality in urban areas were lower than those in rural areas (crude mortality 161.48/100,000 vs. 166.57/100,000; ASMRC 104.57/100,000 vs. 116.42/100,000; ASMRW 103.65/100,000 vs. 115.23/100,000).
Table 2

Estimated cancer mortality in China in 2013.

This Table was published previously and is reproduced with permission from China Cancer [1]

AreaSexDeaths (×1000)Crude mortality (1/105)ASMRC (1/105)ASMRW (1/105)Cumulative rate 0–74 years (%)
AllBoth2229.3163.83109.95108.9412.33
Male1406.2201.67143.08142.3916.22
Female823.1124.0678.5777.378.46
UrbanBoth1180.6161.48104.57103.6511.44
Male735.7197.16134.80134.3315.01
Female444.9124.2876.0574.807.95
RuralBoth1048.7166.57116.42115.2313.38
Male670.5206.86152.93151.8717.65
Female378.2123.8181.5980.439.06

ASMRC age-standardized mortality rate adjusted by the China standard population in 2000, ASMRW age-standardized mortality rate adjusted by the world Segi’s population

Estimated cancer mortality in China in 2013. This Table was published previously and is reproduced with permission from China Cancer [1] ASMRC age-standardized mortality rate adjusted by the China standard population in 2000, ASMRW age-standardized mortality rate adjusted by the world Segi’s population For males, lung cancer was still the most common cancer, with 488,800 new cases, accounting for nearly 1/4 of all cancers (Fig. 1). Gastric cancer ranked the second, followed by liver cancer, colorectal cancer, esophageal cancer, prostate cancer, bladder cancer, pancreatic cancer, lymphoma, and central nerve system tumors. Prostate cancer, which ranked the seventh in 2012 [3], rose to the sixth place in male cancer spectrum. Incidences of colorectal, thyroid, prostate, and pancreatic cancers were higher in urban areas than in rural areas, whereas gastric, liver, and esophageal cancers were more common in rural areas (Fig. 2). Lung cancer ranked the top both in urban and rural areas with similar incidences.
Fig. 1

Incidences of top 10 cancers for males in China, 2013. ASIRW age-standardized incidence rate adjusted by the world Segi’s population, CNS the central nervous system

Fig. 2

ASIRW and ASMRW in urban areas and rural areas for males in China, 2013. ASMRW age-standardized mortality rate adjusted by the world Segi’s population

Incidences of top 10 cancers for males in China, 2013. ASIRW age-standardized incidence rate adjusted by the world Segi’s population, CNS the central nervous system ASIRW and ASMRW in urban areas and rural areas for males in China, 2013. ASMRW age-standardized mortality rate adjusted by the world Segi’s population For females, breast cancer is the most common cancer, with 278,800 new cases (Fig. 3). The incidence of thyroid cancer kept increasing, and thyroid cancer became the fifth most frequent cancer. Incidences of breast, lung, colorectal, thyroid, ovarian cancers were higher in urban areas than in rural areas, whereas gastric, liver, and esophageal cancers were more common in rural areas (Fig. 4).
Fig. 3

Incidences of top 10 cancers for females in China, 2013

Fig. 4

ASIRW and ASMRW in urban areas and rural areas for females in China, 2013

Incidences of top 10 cancers for females in China, 2013 ASIRW and ASMRW in urban areas and rural areas for females in China, 2013 Lung cancer was the leading cause of cancer death in China both in males and females in 2013 (Figs. 5, 6). Liver cancer ranked the second, followed by gastric, esophageal, and colorectal cancers in males (Fig. 5). For females, cancers of gastric, liver, colorectum, and breast ranked the second to fifth most fetal causes of cancer death (Fig. 6). Mortalities of lung, liver, gastric, and esophageal cancers were higher in males than in females. For both sexes, although mortalities of major cancers were different in urban and rural areas, the cancer death patterns were almost the same (Figs. 2, 4). Significant differences with pervious statistics were that prostate cancer incidence ranked the sixth for males in urban areas and colorectal cancer became the second common cause of cancer deaths for females in urban areas in 2013, which ranked the seventh and third in 2012 [3].
Fig. 5

Mortalities of top 10 cancers for males in China, 2013

Fig. 6

Mortalities of top 10 cancers for females in China, 2013

Mortalities of top 10 cancers for males in China, 2013 Mortalities of top 10 cancers for females in China, 2013 The cancer burden still increased compared with that in 2012 [4], even though cancer incidences and mortalities did not change markedly. The coverage of cancer registry keep rising and data quality improving. The estimates of cancer new cases and cancer deaths get more accurate and reliable. As the basis of making anti-cancer policy, conducting research, and providing health care, cancer registration plays a key role in cancer prevention and control in China.
  3 in total

1.  Cancer incidence and mortality in China, 2013.

Authors:  Wanqing Chen; Rongshou Zheng; Siwei Zhang; Hongmei Zeng; Changfa Xia; Tingting Zuo; Zhixun Yang; Xiaonong Zou; Jie He
Journal:  Cancer Lett       Date:  2017-05-03       Impact factor: 8.679

2.  National cancer incidence and mortality in China, 2012.

Authors:  Wanqing Chen; Rongshou Zheng; Tingting Zuo; Hongmei Zeng; Siwei Zhang; Jie He
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

3.  The incidence and mortality of major cancers in China, 2012.

Authors:  Wanqing Chen; Rongshou Zheng; Hongmei Zeng; Siwei Zhang
Journal:  Chin J Cancer       Date:  2016-08-02
  3 in total
  87 in total

1.  Prognosis of FTC compared to PTC and FVPTC: findings based on SEER database using propensity score matching analysis.

Authors:  Zeming Liu; Wen Zeng; Lei Huang; Zhaoyuan Wang; Min Wang; Ling Zhou; Danyang Chen; Haifeng Feng; Wei Zhou; Liang Guo
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

2.  Clinical use of trastuzumab combined with different chemotherapy regimens in multi-line treatment of advanced human epidermal growth factor receptor 2-positive gastric cancer: A case report.

Authors:  Zhe-Ling Chen; Andi Zhao; Pan Li; Mi Zhang; Jiao Yang; Lingxiao Zhang; Xiaoai Zhao; Jin Yang; Le Wang
Journal:  Oncol Lett       Date:  2018-07-25       Impact factor: 2.967

3.  Shear-wave elastography: role in clinically significant prostate cancer with false-negative magnetic resonance imaging.

Authors:  Li-Hua Xiang; Yan Fang; Jing Wan; Guang Xu; Ming-Hua Yao; Shi-Si Ding; Hui Liu; Rong Wu
Journal:  Eur Radiol       Date:  2019-05-29       Impact factor: 5.315

4.  BATF2 reverses multidrug resistance of human gastric cancer cells by suppressing Wnt/β-catenin signaling.

Authors:  Wei Yang; Bian Wu; Ning Ma; Yongfang Wang; Jianhui Guo; Jun Zhu; Sihui Zhao
Journal:  In Vitro Cell Dev Biol Anim       Date:  2019-05-28       Impact factor: 2.416

5.  Spontaneous formation of tumorigenic hybrids between human omental adipose-derived stromal cells and endometrial cancer cells increased motility and heterogeneity of cancer cells.

Authors:  Mingxia Li; Xiaoping Li; Lijun Zhao; Jingyi Zhou; Yuan Cheng; Bo Xu; Jianliu Wang; Lihui Wei
Journal:  Cell Cycle       Date:  2019-01-22       Impact factor: 4.534

6.  Effect of Self-Transcendence Theory Combined with Comprehensive Nursing Intervention under Tumor Nutrition Education on Symptom Improvement, Nutritional Status, and Positive Psychology of Elderly Patients with Gastric Cancer.

Authors:  Xijuan Cui; Tao Shan; Lina Qiao
Journal:  Contrast Media Mol Imaging       Date:  2022-07-12       Impact factor: 3.009

7.  Global expression profiling and pathway analysis of mouse mammary tumor reveals strain and stage specific dysregulated pathways in breast cancer progression.

Authors:  Yan Mei; Jun-Ping Yang; Yan-Hong Lang; Li-Xia Peng; Ming-Ming Yang; Qing Liu; Dong-Fang Meng; Li-Sheng Zheng; Yuan-Yuan Qiang; Liang Xu; Chang-Zhi Li; Wen-Wen Wei; Ting Niu; Xing-Si Peng; Qin Yang; Fen Lin; Hao Hu; Hong-Fa Xu; Bi-Jun Huang; Li-Jing Wang; Chao-Nan Qian
Journal:  Cell Cycle       Date:  2018-05-31       Impact factor: 4.534

8.  12-Epi-Napelline Inhibits Leukemia Cell Proliferation via the PI3K/AKT Signaling Pathway In Vitro and In Vivo.

Authors:  Jia Han; Wei Hou; Bi-Qing Cai; Fan Zhang; Jian-Cai Tang
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-01       Impact factor: 2.629

9.  Incidence, Survival and Prognostic Factors of Oesophagogastric Cancer.

Authors:  Nurul Syuhada Ishak; Hanif Abdul Rahman; Shirley H F Lee; Shir Kiong Lu; Lin Naing
Journal:  J Gastrointest Cancer       Date:  2021-01-04

10.  Long non-coding RNA B3GALT5-AS1 contributes to the progression of gastric cancer via interacting with CSNK2A1.

Authors:  Ping Wang; Guang-Bin Sun; Guang-Xian Dou; Bai-Qing Wang
Journal:  Exp Ther Med       Date:  2021-06-30       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.